Last update 01 Nov 2024

Ibuprofen

Last update 01 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryIbuprofen, a small molecule drug, functions as a COX inhibitor. Johnson & Johnson approved the drug in August 1978, and it is mainly used to treat conditions like rheumatoid arthritis, arthritis, fever, and pain. Ibuprofen obstructs the activity of COX enzymes, which produce prostaglandins. These hormones are involved in inflammation and pain signaling. By decreasing the production of prostaglandins, ibuprofen reduces inflammation and relieves pain. Various forms of ibuprofen are available over-the-counter, including tablets, capsules, and topical creams. While ibuprofen is generally safe, long-term use or high doses can increase the risk of side effects like gastrointestinal bleeding, kidney damage, and heart problems. Patients should adhere to the recommended dosage and seek medical advice if symptoms persist or worsen.

Drug Type

Small molecule drug

Synonyms

(4-isobutylphenyl)-α-methylacetic acid, (RS)-ibuprofen, (±)-2-(p-isobutylphenyl)propionic acid

+ [93]

Target

COX

Mechanism

COX inhibitors(Cyclooxygenases inhibitors)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesCardiovascular Diseases+ [6]

Active Indication

Ductus Arteriosus, PatentChronic PainJuvenile Idiopathic Arthritis+ [27]

Inactive Indication

Acute PainAcute respiratory infectionsAnalgesia+ [15]

Originator Organization

Johnson & Johnson

Active Organization

Overseas Pharmaceuticals Ltd.

Shenyang Shuangding Pharmaceutical Co., Ltd.

Kaken Pharmaceutical Co., Ltd.

+ [19]

Inactive Organization

Oxford Pharmascience Ltd.McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

+ [13]

Drug Highest PhaseApproved

First Approval Date

CN (01 Jan 1966),

ArthritisFeverPain

RegulationOrphan Drug (US), Priority Review (CN)

Structure

Molecular FormulaC13H18O2

InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N

CAS Registry15687-27-1

1,000

Clinical Trials associated with Ibuprofen

CTRI/2024/10/074976 / Not yet recruitingPhase 2/3IIT

A Prospective Randomised Comparative Study Efficacy of IV Paracetamol versus IV Ibuprofen Infusion used as Pre-Emptive Analgesia In Patient Undergoing Elective Laparoscopic Cholecystectomy under General Anaesthesia - NIL

Start Date24 Oct 2024

Sponsor / Collaborator-

CTRI/2024/10/074879 / Not yet recruitingNot Applicable

Analgesic efficacy of transdermal ketoprofen, transdermal diclofenac and oral ibuprofen for post endodontic pain control: A double blinded randomized controlled trial - NIL

Start Date15 Oct 2024

Sponsor / Collaborator

Karthik Enterprises

NCT06539741 / Not yet recruitingNot ApplicableIIT

Mechanisms of Variability in the Analgesic Response to Ibuprofen Following Third Molar Extraction

Nonsteroidal anti-inflammatory drugs (NSAIDs), like ibuprofen, are recommended as first-line treatment for post-surgical dental pain. However, there is variability in analgesic response, and some patients require supplemental opioids for adequate pain relief. The goal of this study is to identify the factors that contribute to the need for opioid after third molar extraction to help limit unnecessary opioid prescriptions in patients who will have good pain relief with ibuprofen alone.

Start Date01 Oct 2024

Sponsor / Collaborator

University of Pennsylvania

[+1]

100 Clinical Results associated with Ibuprofen

100 Translational Medicine associated with Ibuprofen

100 Patents (Medical) associated with Ibuprofen

16,562

Literatures (Medical) associated with Ibuprofen

01 Jan 2025·Journal of Ethnopharmacology

Bioactive phytocompounds profiling and the evaluation of analgesic, anti-inflammatory, and antihyperglycemic potential of Argyreia capitiformis (Poir.) Ooststr.: A combined n vitro, n vivo, and computational investigations

Article

Author: Islam, Md Naharul ; Biswas, Biswajit ; Islam, Md. Naharul ; Oisay, Debasree Sen ; Hasan, Md Nazmul ; Hasan, Md. Nazmul ; Biswas, Partha ; Medha, Maisha Maliha ; Devnath, Hiron Saraj ; Hossain, Arafat ; Sadhu, Samir Kumar ; Ahmed, Khondoker Shahin ; Hossain, Hemayet

ETHNOPHARMACOLOGICAL RELEVANCEArgyreia capitiformis (Poir.) Ooststr. (Convolvulaceae) is traditionally used by the Chakma community in the hilly region of Bangladesh to treat minor disorders such as pain.AIM OF THE STUDYThis study intended to determine the secondary metabolites to identify bioactive compounds and evaluate antioxidant potential, in vitro anti-inflammatory and in vivo analgesic, anti-inflammatory, and antihyperglycemic activities of A. capitiformis along with in silico investigations.MATERIALS AND METHODSChemical profiling was carried out using HPLC and GC-MS analysis. The analgesic effect was measured employing tail immersion and acetic acid-induced writhing methods. Following protein denaturation and formalin-induced paw edema, anti-inflammatory activity was studied. The antihyperglycemic potential was assessed using an oral glucose tolerance test (OGTT), while further mechanistic investigation was conducted using an alpha-glucosidase enzyme inhibitory assay. Simulations and molecular docking analyses were performed to ascertain the stability and binding affinities of the drug-protein complex.RESULTSA. capitiformis ethanolic extract confirmed the presence of phenolics, alkaloids, flavonoids, terpenoids, tannins, gums, steroids, and reducing sugars. HPLC analysis revealed the presence of eight polyphenolic compounds, the most abundant of which was myricetin (64.10 ± 0.14 mg per 100 g dry extract). Moreover, the GC-MS analysis revealed twenty-four molecules, the most important of which was 2,4-bis (dimethylbenzyl)-6-t-butylphenol (9.19%). The concentrations of total flavonoids, total terpenoids, total phenolics, and total tannins were ascertained to be 142.48 mg QE/g, 173.1 mg UAE/g, 19.35 mg GAE/g, and 13.05 mg GAE/g, respectively. Furthermore, the plant extract had a total antioxidant capacity of 388 mg AAE/g. In the writhing assay, the plant extract suppressed writhing by 59.73% and 76.99% at the doses of 250 and 500 mg/kg, respectively, compared to the standard diclofenac Na 87.17%, and in the tail immersion assay, the plant extract displayed a maximum average reaction time of 1.94 and 2.40 s at the doses of 250 and 500 mg/kg, respectively as compared to the control tramadol 2.84 s at 60 min. In an in vitro anti-inflammatory assay, the plant extract possessed an IC₅₀ of 95.51 μg/ml while diclofenac Na (standard drug) was found to be 69.50 μg/ml. Afterward, in vivo anti-inflammatory activity was observed in mice over a period, particularly after 3 h, the plant extract exerted maximum percent inflammation inhibitions of 36.36% and 45.45% at the doses of 250 and 500 mg/kg, respectively whereas ibuprofen the standard drug (100 mg/kg) exhibited 61.82%. The plant extract demonstrated antihyperglycemic activity, lowering blood sugar levels to 5.7 and 4.62 mM at doses of 250 and 500 mg/kg, respectively, as opposed to 8.58 mM in the control group. Meanwhile, the standard drug glibenclamide (5 mg/kg) dropped blood glucose levels to 2.38 mM in 60 min after glucose administration. Molecular docking (MD) and molecular dynamics simulation (MDS) studies support the stability of the protein complex responsible for exerting pharmacological activities.CONCLUSIONA. capitiformis extract exhibited strong medicinal values supporting its traditional uses.

01 Jan 2025·The Journal of Pediatrics

Assessment of Blood Prostaglandin E2 Metabolite Levels among Infants Born Preterm with Patent Ductus Arteriosus: A Prospective Study

Article

Author: Nagafuji, Motomichi ; Fujiyama, Satoshi ; Hitaka, Daisuke ; Takada, Hidetoshi ; Homma, Masato ; Doki, Kosuke ; Takeuchi, Shusuke ; Okada, Yuki ; Saito, Makoto ; Nakamura, Yuri ; Kanai, Yu ; Hanaki, Mai ; Miyazono, Yayoi ; Ishii, Ryota

OBJECTIVETo assess the role of prostaglandin E₂ by measuring blood prostaglandin E₂ metabolite (PGEM) concentrations in preterm infants with patent ductus arteriosus (PDA).STUDY DESIGNA prospective observational study of preterm infants born before 32 weeks of gestational age (GA) was performed in a single tertiary hospital in Japan. Blood samples were collected to measure serum concentrations of PGEM, ibuprofen (IBU), and cytokines. Multiple regression analyses assessed associations between blood PGEM levels and perinatal factors, development of hemodynamically significant PDA (hsPDA), and IBU treatment response of hsPDA.RESULTSSeventy-nine infants (median GA 28 weeks) were enrolled in this study. Forty-seven received IBU for hsPDA treatment 1 d after birth in median. PDA closure occurred in 25 infants after a single IBU treatment. Serum PGEM concentrations were associated with histologic chorioamnionitis (P < .01), but not with GA, respiratory distress syndrome, or serum IL-6 concentrations. Serum PGEM concentrations decreased after initial IBU treatment; however, they were not associated with hsPDA development (P = .39). IBU concentrations correlated with IBU treatment response (aOR 1.29, P < .01). However, pre-IBU serum PGEM levels and PGEM reduction ratio did not (P = .13, .15, respectively).CONCLUSIONSSerum PGEM concentrations in preterm infants were associated with maternal histologic chorioamnionitis, but not hsPDA development. IBU treatment response was associated with higher blood IBU concentrations, but not PGEM concentrations.

01 Jan 2025·Food Chemistry

Green synthesis and two-step chromatographic separation of thiocanthal and thiocanthol: Two novel biologically active sulfur derivatives of oleocanthal and oleacein from extra virgin olive oil

Article

Author: Gasparrini, Francesco ; Villani, Claudio ; Di Risola, Daniel ; Fontana, Mario ; Federico, Rodolfo ; Mosca, Luciana ; Francioso, Antonio ; Mattioli, Roberto ; Dufrusine, Beatrice ; Pascarella, Gianmarco ; Morea, Veronica ; Ciogli, Alessia ; Dainese, Enrico

Oleocanthal and oleacein are the two major secoiridoids exclusively present in extra virgin olive oil (EVOO). Both compounds exert important pharmacological activities, including anti-inflammatory, anti-tumoral, neuro- and cardiovascular protective effects. Due to their enormous potential as possible drugs the extraction of these two bioactive natural products from EVOO has been extensively investigated in the last years and is generally supported by the use of organic chemistry. It is quite difficult to produce large quantities of these two compounds, either by organic solvent extraction and purification or by chemical synthesis, and furthermore organic processes such as cleaning, defatting, and extraction of EVOO pose a threat to the environment and are potentially harmful to workers. In this work we set up a novel aqueous extraction and isolation method from EVOO by transforming oleocanthal and oleacein into two water-soluble sulfonated products. The two derived compounds, here named thiocanthal and thiocanthol, were isolated by a two-step organic free chromatographic strategy, chemically characterized, and evaluated for their inhibitory activity on cyclooxygenase (COX). The results demonstrate that thiocanthal and thiocanthol possess anti-inflammatory effect, which is comparable to their precursors and higher than the well-known non-steroidal anti-inflammatory drug ibuprofen. Computational docking studies were performed to obtain and analyse putative models of the interaction of thiocanthal and thiocanthol with COX-1 and COX-2 binding sites. Predicted binding energy values suggested that both compounds might preferentially bind COX-2, which may have a significant pharmacological impact. Therefore, thiocanthal and thiocanthol, obtained by this novel green process, are extremely interesting both as new bioactive compounds per se and as lead compounds for the development of novel non-steroidal anti-inflammatory drugs (NSAIDs).

132

News (Medical) associated with Ibuprofen

25 Sep 2024

·www.prnewswire.com

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

- The VAN has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time - The VAN is expected to launch in Q4 2024 SAN DIEGO, Sept. 25, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved the Company's Prior Approval Supplement Application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN. The VAN will replace the current vented vial spike and has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time down to between twenty and forty-five seconds. The user-friendly "container-like" design of the VAN may enhance the safe use of ZYNRELEF, increase adoption, and improve the preparation process. "With this approval, we are providing healthcare providers with a new mechanism that directly addresses one of ZYNRELEF's adoption hurdles and will help reduce preparation time for surgical staff," said Bill Forbes, PharmD, Executive Vice President, Chief Development Officer at Heron. "Reducing patients' pain during the first three days after surgery is critical for patient recovery and well-being following often painful procedures, and we anticipate the VAN will lead to increased ZYNRELEF adoption, positively impacting patient recovery." "The VAN approval, along with ZYNRELEF's January label expansion, its inclusion in the proposed 2025 Non-Opioid Policy for Pain Relief ("NOPAIN Act"), and the continued integration of our partnership with CrossLink Life Sciences, LLC ("CrossLink"), are all exciting milestones achieved during 2024 contributing to ZYNRELEF's continued progress," said Craig Collard, Chief Executive Officer at Heron. "We remain optimistic about the potential transformative impact the VAN will have, following its expected launch in Q4 2024, providing healthcare professionals with an easier to use, versatile, and effective solution for managing postoperative pain across a wide range of surgical procedures." About ZYNRELEF for Postoperative Pain ZYNRELEF is the first and only dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam. ZYNRELEF is the first and only extended-release local anesthetic to demonstrate in Phase 3 studies significantly reduced pain and significantly increased proportion of patients requiring no opioids through the first 72 hours following surgery compared to bupivacaine solution, the current standard-of-care local anesthetic for postoperative pain control. ZYNRELEF was initially approved by the FDA in May 2021 for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty. In December 2021, the FDA approved an expansion of ZYNRELEF's indication to include foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures. On January 23, 2024, the FDA approved ZYNRELEF for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures. Important Safety Information for Patients ZYNRELEF contains an NSAID (non-steroidal anti-inflammatory drug), a type of medicine which: can increase the risk of a heart attack or stroke that can lead to death. This risk increases with higher doses and longer use of an NSAID. cannot be used during heart bypass surgery. can increase the risk of gastrointestinal bleeding, ulcers, and tears. ZYNRELEF should also not be used: if you are allergic to any component of ZYNRELEF, similar local anesthetics, aspirin or other NSAIDs (such as ibuprofen or naproxen), or have had an asthma attack, hives, or other allergic reaction after taking any of these medicines. as a paracervical block, during childbirth. The most common side effects of ZYNRELEF are soft tissue procedures: vomiting and orthopedic procedures: constipation and headache. The medicines in ZYNRELEF (a local anesthetic and an NSAID) may affect the nervous and cardiovascular system; may cause liver or kidney problems; may reduce the effects of some blood pressure medicines; should be avoided if you have severe heart failure; may cause adverse effects on cartilage; may cause a rare blood disorder, or life-threatening skin or allergic reactions; may harm your unborn baby if received at 20 weeks of pregnancy or later; and may cause low red blood cells (anemia). Tell your healthcare provider about all your medical conditions and about all the medicines you take including prescription or over-the-counter medicines, vitamins, or herbal supplements to discuss if ZYNRELEF is right for you. Talk to your healthcare provider for medical advice about side effects. Report side effects to Heron at 1-844-437-6611 or to FDA at 1-800-FDA-1088 or . The information provided here is not comprehensive. Please see full Prescribing Information, including Boxed Warning, at . About Heron Therapeutics, Inc. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit . Forward-looking Statements This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding the potential market opportunities for ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL®; revenue, adjusted EBITDA and other financial guidance provided by the Company; the results of the commercial launch of APONVIE; the potential additional market opportunity for the expanded U.S. label for ZYNRELEF; the timing of the Company's development of the VAN program and receipt of required regulatory approvals; the realization of anticipated benefits from receipt of required regulatory approvals and/or launch of the VAN; the Company's ability to establish and maintain successful commercial arrangements like our co-promotion agreement with CrossLink; the realization of anticipated benefits from our co-promotion agreement with CrossLink; the outcome of the Company's pending abbreviated new drug application litigation; whether the Company is required to write-off any additional inventory in the future; the expected future balances of Heron's cash, cash equivalents and short-term investments; the expected duration over which Heron's cash, cash equivalents and short-term investments balances will fund its operations and the risk that future equity financings may be needed; any inability or delay in achieving profitability. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law. Investor Relations and Media Contact: Ira Duarte Executive Vice President, Chief Financial Officer Heron Therapeutics, Inc. [email protected] 858-251-4400 SOURCE Heron Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalPhase 3

23 Sep 2024

·www.drugs.com

Review Compares Drug Interventions for Acute Migraine Treatment

MONDAY, Sept. 23, 2024 -- All active interventions show superior efficacy to placebo for freedom from pain, and most do for sustained pain freedom, for the acute treatment of migraine among adults, according to a review published online Sept. 18 in The BMJ . William K. Karlsson, from the Danish Headache Centre at Copenhagen University Hospital-Rigshospitalet, and colleagues conducted a systematic review and network meta-analysis to compare all licensed drug interventions as oral monotherapy for acute treatment of migraine episodes in adults. Data were included from 137 randomized controlled trials involving 89,445 participants allocated to one of 17 active interventions or placebo. The researchers found that compared with placebo, all active interventions showed superior efficacy for pain freedom at two hours (odds ratios from 1.73 for naratriptan to 5.19 for eletriptan), and most also showed superior efficacy for sustained pain freedom to 24 hours (odds ratios from 1.71 for celecoxib to 7.58 for ibuprofen). Eletriptan was the most effective drug for pain freedom at two hours in head-to-head comparisons (odds ratios from 1.46 to 3.01), followed by rizatriptan, sumatriptan, and zolmitriptan (odds ratios, 1.59 to 2.44, 1.35 to 2.04, and 1.47 to 1.96, respectively). The most efficacious interventions for sustained pain freedom were eletriptan and ibuprofen (odds ratios from 1.41 to 4.82). "The results of this systematic review and network meta-analysis offer the best available evidence to guide the choice of acute oral drug interventions for migraine episodes," the authors write. "Our results are in line with recent observational evidence." Several authors disclosed ties to the biopharmaceutical industry. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

23 Sep 2024

·www.biopharmadive.com

Data advancements are finally unlocking drug safety during pregnancy

In the late 1950s, the thalidomide disaster rightfully kicked off an ongoing and intense scrutiny of pregnancy drug side effects. Untested in pregnant women and initially thought to be safe, the sedative and morning sickness treatment resulted in serious birth defects globally. However, thanks to then-FDA reviewer Frances Kelsey, thalidomide was not permitted to enter the U.S. Since the thalidomide chapter, many FDA-approved drugs have been deemed unsafe for pregnant women. Acne-treating oral retinoids can cause severe birth defects; blood thinners like warfarin can precipitate bleeding in newborns; and regular use of pain-relieving NSAIDs like ibuprofen may increase the risk of miscarriage. For years, the pendulum has swung understandably towards safeguarding the health of the fetus. But with pre-existing chronic conditions like type 2 diabetes, autoimmune diseases, and mental health conditions on the rise, the health of the mother must remain in focus. Women with pre-existing anxiety or depression, for example, cant simply forgo their medication or reduce their dose. Anxiety and mood swings for the mother can impact the fetus (or newborn, if the mother develops post-partum depression) in a more harmful way than the medication itself. The delicate balance of drug development & administration Pregnant women are generally excluded from randomized controlled clinical trials of medications, requiring researchers to rely on real-world studies. However, real-world studies can be less reliable indicators of effectiveness and safety due to confounding factors and bias. The pregnancy window of effect further complicates this process; a product that is injurious to the fetus in the first trimester may not be in the third trimester once certain developmental milestones have passed. Finally, the fact that pregnant women may take multiple medications at a time means it can be difficult to pinpoint the true cause of untoward outcomes such as fetal injury or loss.Treatment guidelines in pregnancy have historically prioritized fetal health. With advances in technology, the medical sector has been able to harvest rich, multimodal data on how treatment protocols affect the mother-fetus pair. Drugmakers have conducted large observational studies that follow pregnant women who take medications, like The National Birth Defects Prevention Study (NBDPS). Data collection has matured to include drug micro-dosing, organ-on-a-chip technology, and earlier-stage fetal monitoring. Continued forward movement for the industry involves a balanced approach between the health and safety of the mom-baby dyad, and innovative data collection methods that inform that balance. New data sources and collection techniquesStanford Medicine, for example, is improving data collection techniques for pregnant individuals through wearable devices and sensors. Their devices collect real-time data on various physiological parameters such as the mothers heart rate, sleep patterns and physical activity. These biomarkers can then be correlated with pregnancy outcomes. Stanfords study of wearable device data from 1,000 pregnant women in 2023 showed that poor sleep and reduced activity in pregnancy increases the risk of premature birth. The rise of digital data in healthcare is fostering growth in repositories of patient data, including prenatal care, medication use, lab results, dietary habits, environmental stressors, and other factors offering rich opportunities for analysis. As access to these data grows, emerging technologies in machine learning (ML), artificial intelligence (AI), and natural language processing (NLP) will have a greater impact on product development and administration. AI/ML techniques can be applied to large datasets to identify complex relationships between maternal and fetal factors and pregnancy outcomes. Through NLP and real-world data analysis, both drugmakers and HCPs can extract information from unstructured data like clinical notes and social media to gain a greater understanding of the safety and effectiveness of interventions in real-world settings. Its important to note that almost all the new technologies being used in pregnancy-related data collection and analysis are still nascent. For example, gestational age which involves precise calibration of the developmental stage of the fetus can potentially be found in or estimated with EHR and/or claims data, but the accuracy of the datapoints employed varies. Because of privacy concerns, precise birth dates may be masked (offering only month and year of birth but not the date). As these technologies evolve and more accurate algorithms are developed, more precise data on gestational age means that researchers can better assess the potential risks of treatment exposure within specific timeframes. Data sources that pre-link the mother-infant pair (or pairs, in multiple birth events) and include an analytics module that is designed to interrogate the paired object(s) are a big step towards more intuitive and rapid analysis. This can be especially helpful when a safety issue that arises needs contextualization and workup.Ensuring drug exposure awareness in pregnancy continues to be a priorityApps such as MommyMeds can be consulted by pregnant women and their healthcare providers (HCPs) to verify the safety of specific medications during pregnancy or breastfeeding. Moreover, patients and their HCPs can consult reputable databases and websites such as BUMPS and The Cleveland Clinic. Finally, guidelines on treatments in pregnancy are available from the American College of Obstetricians and Gynecologists and the FDA. Pregnant woman and their HCPs are more empowered than ever to tap into an evolving, multi-faceted compendium of information on real-time pregnancy exposures. Weve come a long way in sixty years, and enhancements in data collection, data linkage, and analytic methods will improve pregnancy outcomes in the next sixty.Interested in how Panalgo can help your company with mother-infant linked data to enhance pregnancy data? Contact us. '

100 Deals associated with Ibuprofen

External Link

KEGG	Wiki	ATC	Drug Bank
D00126	Ibuprofen	M02AA13 R02AX02 M01AE01 G02CC01 C01EB16	DB01050

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Ductus Arteriosus, Patent	EU	Recordati Rare Diseases, Inc.	28 Jul 2004
Ductus Arteriosus, Patent	LI	Recordati Rare Diseases, Inc.	28 Jul 2004
Ductus Arteriosus, Patent	IS	Recordati Rare Diseases, Inc.	28 Jul 2004
Ductus Arteriosus, Patent	NO	Recordati Rare Diseases, Inc.	28 Jul 2004
Chronic Pain	AU	Viatris Pty Ltd.	12 Nov 2001
Juvenile Idiopathic Arthritis	AU	Viatris Pty Ltd.	12 Nov 2001
Osteoarthritis	AU	Viatris Pty Ltd.	12 Nov 2001
Primary dysmenorrhea	AU	Viatris Pty Ltd.	12 Nov 2001
Acute upper respiratory infection	JP	Kaken Pharmaceutical Co., Ltd.	25 Jun 1971
Inflammation	JP	Kaken Pharmaceutical Co., Ltd.	25 Jun 1971
Rheumatoid Arthritis	GB	Johnson & Johnson	01 Jan 1969
Arthritis	CN	Dan Dong Yi Chuang Yao Ye You Xian Ze Ren Gong Si	01 Jan 1966
Fever	CN	Dan Dong Yi Chuang Yao Ye You Xian Ze Ren Gong Si	01 Jan 1966
Pain	CN	Dan Dong Yi Chuang Yao Ye You Xian Ze Ren Gong Si	01 Jan 1966

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fever	NDA/BLA	TH	Cumberland Pharmaceuticals, Inc.	01 Jun 2002
Pain	NDA/BLA	US	McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.	19 Sep 1974
Osteoarthritis	Phase 3	US	McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.	19 Sep 1974
Pain	Phase 3	US	McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.	19 Sep 1974
Fever	Preclinical	TH	Cumberland Pharmaceuticals, Inc.	01 Jun 2002
Pain	Preclinical	US	McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.	19 Sep 1974

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04611529 (CTgov)	Phase 4	Acute low back pain	198	Topical diclofenac+Ibuprofen 400 mg (Oral Ibuprofen + Topical Diclofenac)	quxhxkqjbw(swcudpopsh) = addtrrrsvq fmboydwsec (chrvdadfam, yxpyqwrljd - dtebgomzbd) View more	-	09 Oct 2024
				Ibuprofen 400 mg (Oral Ibuprofen + Topical Placebo)	quxhxkqjbw(swcudpopsh) = tnoufwptpo fmboydwsec (chrvdadfam, ezetpdzarg - hdhvgwtcun) View more
NCT05737069 (CTgov)	Phase 1	Pain	84	Ibuprofen Arginine (Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Test))	amlqyukwju(vzzdubcmel) = nrdzpdxgfq eqdvisztbh (utxfwufjsr, hooxbetnvq - glwnoiayrn) View more	-	19 Sep 2024
				Ibuprofen Arginine (Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Spedifen) (Reference))	amlqyukwju(vzzdubcmel) = kjpusiisvs eqdvisztbh (utxfwufjsr, ajapprovfe - gcbddgfmmm) View more
NCT03859024 (CTgov)	Phase 4	Urethral Stricture \| Pain, Postoperative	48	Acetaminophen+Ibuprofen 800 mg+Oxycodone (Standard Protocol)	inwtonzvtq(gxuqpllzjj) = xwrkvrrztn nwqyapgbpw (rwpqobhzen, qadnpsxoer - mckicuchxa) View more	-	19 Sep 2024
				Acetaminophen+Ibuprofen 800 mg+celebrex+Dexamethasone+Oxycodone+Bupivacaine+Gabapentin (Enhanced Recovery Protocol)	inwtonzvtq(gxuqpllzjj) = sobdqoqzwi nwqyapgbpw (rwpqobhzen, ztwsnlthwf - wfxbpwwgvi) View more
NCT03749616 (Adult NSAID, CTgov)	Phase 4	Pain \| Radius Fractures	32	Acetaminophen (Acetaminophen)	dptxcmnjfs(gsfgwxbtgj) = mzcpgmtvqv nessdrmfqo (xkedbywlmv, nbdrepfrcz - qvmtcxnadc) View more	-	05 Sep 2024
				Ibuprofen (NSAID)	dptxcmnjfs(gsfgwxbtgj) = zeihrstilr nessdrmfqo (xkedbywlmv, crzocgjpfj - dogarpdphg) View more
NCT04879823 (CTgov)	Phase 3	Analgesia	222	Acetaminophen+Ibuprofen+Dexamethasone (Dexamethasone)	epfmdejgdi(lfsisewhms) = ipyhcluxxo aimbiiqboe (doqvcxsaws, uumqnhwqhk - phpcyjpsdm) View more	-	05 Sep 2024
				Placebo+Acetaminophen+Ibuprofen (Placebo)	epfmdejgdi(lfsisewhms) = fsaaxhhvqj aimbiiqboe (doqvcxsaws, rtnfmvtbmj - asglqtntlm) View more
NCT03929640 (CTgov)	Phase 3	Pain, Postoperative	49	Placebo+Ibuprofen (Ibuprofen and Placebo)	xpowlwuluy(gmsebdnegv) = rdbecfpfha iyqjwkdapa (wmaescdcxb, eqjrlgbacd - chbsaryxgf) View more	-	04 Sep 2024
				Acetaminophen+Ibuprofen (Ibuprofen and Acetaminophen)	xpowlwuluy(gmsebdnegv) = iwowkiycbp iyqjwkdapa (wmaescdcxb, fqqusitovo - txmjaspukw) View more
NCT04791761 (CTgov)	Phase 1/2	Pain, Postoperative	73	Opioid disposal education+Acetaminophen+Ibuprofen+Oxycodone (Opioid Pain Control)	dhkmbxsrho(jkjptnuksr) = sqtqbygrgg uasdqnydll (wsvyitxjgf, krpnohnrrg - cmswpzpehq) View more	-	16 Aug 2024
				Acetaminophen+Ibuprofen (Non-opioid Pain Control)	dhkmbxsrho(jkjptnuksr) = lyostgovbk uasdqnydll (wsvyitxjgf, irhdixrnpr - buvvignned) View more
NCT03399318 (Pubmed)	Phase 3	Malaria	256	Aggressive antipyretic therapy (acetaminophen + ibuprofen)	ftkiexutyc(nassvswaes) = pufkulafnn odkezeaxym (lavjcbsnvx, -0.62) View more	Positive	10 Jun 2024
				Usual care (acetaminophen alone)	ftkiexutyc(nassvswaes) = zmcndimsps odkezeaxym (lavjcbsnvx, -0.82 to -0.42) View more
NCT03785756 (CTgov)	Phase 3	Pain	280	Placebo of IR tablet+Ibuprofen 300 mg Oral Tablet (Prolonged Release Group)	seidwmkkgl(eifqesiudv) = ucktttmasi yksayxiuzh (wtltwkdzzf, tbugfxznuw - gpgiadtflv) View more	-	03 Jun 2024
				Placebo of IR tablet+Ibuprofen 200 mg Oral Tablet (Immediate Release Group)	seidwmkkgl(eifqesiudv) = tawpcatcxq yksayxiuzh (wtltwkdzzf, ldikwhrduv - kdymhasumi) View more
NCT02929589 (CTgov)	Phase 3	Hernia \| Pain, Postoperative	18	ibuprofen (Opioid naïve Patients-Group A)	qdawptzndz(qandwlcppr) = rlosnktzir oywkoaevev (zmgrnhtymp, skazpczuco - rlgnehmhrk) View more	-	26 Mar 2024
				Opioid medication+Ibuprofen (Non-Opioid naïve Patients-Group C)	slnnvljfok(ulabykngvi) = izcspismnb tlmypnvypd (ybqcpypawz, cbvsvqpyvj - ccmejzeokg) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis